Xilio Therapeutics Unveils New Stock Option Grants for Employees Under 2022 Inducement Plan

Reuters
08-02
<a href="https://laohu8.com/S/XLO">Xilio Therapeutics</a> Unveils New Stock Option Grants for Employees Under 2022 Inducement Plan

WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company, announced the granting of non-qualified stock options to purchase 134,000 shares of its common stock to two new employees under its 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.65 per share, reflecting the closing price on August 1, 2025. Each option has a ten-year term, with 25% vesting on the first anniversary of employment commencement and the remaining 75% vesting in 36 equal monthly installments, contingent on continued service. These grants comply with Nasdaq Listing Rule 5635(c)(4).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9504891-en) on August 01, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10